Symbols / PTGX $102.89 -0.86% Protagonist Therapeutics, Inc.
PTGX Chart
About
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.57B |
| Enterprise Value | 6.07B | Income | -130.15M | Sales | 46.02M |
| Book/sh | 9.82 | Cash/sh | 8.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 132 | IPO | — |
| P/E | — | Forward P/E | -236.95 | PEG | — |
| P/S | 142.67 | P/B | 10.47 | P/C | — |
| EV/EBITDA | -38.67 | EV/Sales | 131.80 | Quick Ratio | 12.59 |
| Current Ratio | 12.71 | Debt/Eq | 1.68 | LT Debt/Eq | — |
| EPS (ttm) | -2.05 | EPS next Y | -0.43 | EPS Growth | — |
| Revenue Growth | -95.60% | Earnings | 2026-05-06 | ROA | -13.99% |
| ROE | -20.18% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -6.77% | Profit Margin | -282.83% | Shs Outstand | 63.81M |
| Shs Float | 51.90M | Short Float | 15.07% | Short Ratio | 12.45 |
| Short Interest | — | 52W High | 107.84 | 52W Low | 39.60 |
| Beta | 2.11 | Avg Volume | 813.93K | Volume | 469.63K |
| Target Price | $112.42 | Recom | Strong_buy | Prev Close | $103.78 |
| Price | $102.89 | Change | -0.86% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-19 | main | Leerink Partners | Outperform → Outperform | $110 |
| 2026-03-19 | main | JP Morgan | Overweight → Overweight | $106 |
| 2026-03-19 | main | Citigroup | Buy → Buy | $125 |
| 2026-03-19 | main | Barclays | Overweight → Overweight | $119 |
| 2026-03-03 | main | Goldman Sachs | Neutral → Neutral | $95 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $100 |
| 2026-02-26 | main | Barclays | Overweight → Overweight | $113 |
| 2026-02-26 | main | Citizens | Market Outperform → Market Outperform | $112 |
| 2026-02-02 | main | Jefferies | Buy → Buy | $118 |
| 2026-01-30 | main | HC Wainwright & Co. | Buy → Buy | $117 |
| 2026-01-05 | main | Truist Securities | Buy → Buy | $110 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $108 |
| 2025-12-08 | main | Citigroup | Buy → Buy | $115 |
| 2025-11-10 | main | Citigroup | Buy → Buy | $98 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $81 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $88 |
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $102 |
| 2025-10-28 | main | Truist Securities | Buy → Buy | $88 |
| 2025-10-28 | main | Wedbush | Outperform → Outperform | $86 |
| 2025-10-28 | reit | BTIG | Buy → Buy | $82 |
- PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill hu, 02 Apr 2026 07
- Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge - Yahoo Finance Sat, 04 Apr 2026 05
- Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN Wed, 01 Apr 2026 20
- PTGX SEC Filings - Protagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 07
- Protagonist Therapeutics stock hits all-time high at 105.71 USD - Investing.com ue, 31 Mar 2026 20
- Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 02 Apr 2026 21
- Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat Wed, 25 Mar 2026 07
- Responsive Playbooks and the PTGX Inflection - Stock Traders Daily ue, 10 Mar 2026 07
- Insider Sale: President and CEO of $PTGX Sells 59 Shares - Quiver Quantitative Wed, 25 Mar 2026 07
- PTGX Jul 2026 55.000 put (PTGX260717P00055000) Stock Historical Prices & Data - ca.finance.yahoo.com Fri, 03 Apr 2026 21
- Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC - MarketBeat Sat, 14 Mar 2026 07
- Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock - Investing.com ue, 27 Jan 2026 08
- PTGX Apr 2026 60.000 call (PTGX260417C00060000) Stock Price, News, Quote & History - ca.finance.yahoo.com hu, 02 Apr 2026 07
- Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade - MarketBeat hu, 19 Mar 2026 07
- PTGX Apr 2026 70.000 put (PTGX260417P00070000) Interactive Stock Chart - ca.finance.yahoo.com Fri, 03 Apr 2026 21
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
46.02
-89.41%
|
434.43
+624.06%
|
60.00
+125.73%
|
26.58
|
| Operating Revenue |
|
46.02
-89.41%
|
434.43
+624.06%
|
60.00
+125.73%
|
26.58
|
| Operating Expense |
|
204.14
+12.42%
|
181.59
+18.18%
|
153.65
-2.72%
|
157.95
|
| Research And Development |
|
159.29
+15.32%
|
138.13
+14.95%
|
120.16
-4.80%
|
126.22
|
| Selling General And Administration |
|
44.85
+3.20%
|
43.46
+29.77%
|
33.49
+5.52%
|
31.74
|
| General And Administrative Expense |
|
44.85
+3.20%
|
43.46
+29.77%
|
33.49
+5.52%
|
31.74
|
| Other Gand A |
|
44.85
+3.20%
|
43.46
+29.77%
|
33.49
+5.52%
|
31.74
|
| Total Expenses |
|
204.14
+12.42%
|
181.59
+18.18%
|
153.65
-2.72%
|
157.95
|
| Operating Income |
|
-158.13
-162.54%
|
252.84
+369.98%
|
-93.65
+28.71%
|
-131.37
|
| Total Operating Income As Reported |
|
-158.13
-162.54%
|
252.84
+369.98%
|
-93.65
+28.71%
|
-131.37
|
| EBITDA |
|
-156.85
-161.83%
|
253.67
+373.72%
|
-92.67
+28.90%
|
-130.34
|
| Normalized EBITDA |
|
-156.85
-161.83%
|
253.67
+373.72%
|
-92.67
+28.90%
|
-130.34
|
| Reconciled Depreciation |
|
1.28
+54.96%
|
0.83
-15.46%
|
0.98
-5.51%
|
1.03
|
| EBIT |
|
-158.13
-162.54%
|
252.84
+369.98%
|
-93.65
+28.71%
|
-131.37
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Pretax Income |
|
-129.31
-146.28%
|
279.41
+453.88%
|
-78.95
+38.02%
|
-127.39
|
| Net Non Operating Interest Income Expense |
|
28.79
+9.40%
|
26.32
+76.63%
|
14.90
+266.95%
|
4.06
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
28.79
+9.40%
|
26.32
+76.63%
|
14.90
+266.95%
|
4.06
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
28.79
+9.40%
|
26.32
+76.63%
|
14.90
+266.95%
|
4.06
|
| Interest Income |
|
28.79
+9.40%
|
26.32
+76.63%
|
14.90
+266.95%
|
4.06
|
| Other Income Expense |
|
0.03
-89.20%
|
0.25
+224.38%
|
-0.20
-151.25%
|
-0.08
|
| Other Non Operating Income Expenses |
|
0.03
-89.20%
|
0.25
+224.38%
|
-0.20
-151.25%
|
-0.08
|
| Tax Provision |
|
0.84
-80.14%
|
4.22
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+1300.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Net Income From Continuing Operation Net Minority Interest |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Net Income From Continuing And Discontinued Operation |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Net Income Continuous Operations |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Normalized Income |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Net Income Common Stockholders |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Diluted EPS |
|
-2.05
-148.46%
|
4.23
+404.32%
|
-1.39
+46.54%
|
-2.60
|
| Basic EPS |
|
-2.05
-145.86%
|
4.47
+421.58%
|
-1.39
+46.54%
|
-2.60
|
| Basic Average Shares |
|
63.57
+3.26%
|
61.57
+8.46%
|
56.76
+15.74%
|
49.04
|
| Diluted Average Shares |
|
63.57
-2.31%
|
65.08
+14.65%
|
56.76
+15.74%
|
49.04
|
| Diluted NI Availto Com Stockholders |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
668.19
-10.28%
|
744.73
+108.05%
|
357.95
+44.38%
|
247.93
|
| Current Assets |
|
577.57
-2.38%
|
591.64
+66.39%
|
355.58
+46.28%
|
243.08
|
| Cash Cash Equivalents And Short Term Investments |
|
567.36
+35.44%
|
418.91
+22.63%
|
341.62
+43.93%
|
237.35
|
| Cash And Cash Equivalents |
|
128.39
+32.02%
|
97.25
-47.92%
|
186.73
+48.50%
|
125.74
|
| Other Short Term Investments |
|
438.97
+36.47%
|
321.66
+107.67%
|
154.89
+38.78%
|
111.61
|
| Receivables |
|
4.50
-97.33%
|
168.49
+1530.76%
|
10.33
+19769.23%
|
0.05
|
| Other Receivables |
|
0.01
-95.97%
|
0.25
+226.32%
|
0.08
+80.95%
|
0.04
|
| Taxes Receivable |
|
—
|
—
|
—
|
0.00
|
| Accrued Interest Receivable |
|
4.37
+34.64%
|
3.24
+1166.41%
|
0.26
|
—
|
| Prepaid Assets |
|
5.71
+34.83%
|
4.24
+16.81%
|
3.63
-36.01%
|
5.67
|
| Restricted Cash |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
—
|
—
|
—
|
0.04
|
| Total Non Current Assets |
|
90.61
-40.81%
|
153.08
+6348.36%
|
2.37
-51.06%
|
4.85
|
| Net PPE |
|
11.69
-7.28%
|
12.61
+486.64%
|
2.15
-53.55%
|
4.63
|
| Gross PPE |
|
20.00
+1.84%
|
19.64
+134.31%
|
8.38
-15.15%
|
9.88
|
| Accumulated Depreciation |
|
-8.31
-18.19%
|
-7.04
-12.85%
|
-6.23
-18.65%
|
-5.25
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.49
+3.04%
|
1.45
+26.60%
|
1.14
+4.96%
|
1.09
|
| Other Properties |
|
15.58
-1.23%
|
15.77
+151.25%
|
6.28
-20.32%
|
7.88
|
| Leases |
|
2.94
+21.12%
|
2.42
+151.71%
|
0.96
+5.48%
|
0.91
|
| Investments And Advances |
|
78.64
-43.93%
|
140.25
|
0.00
|
—
|
| Other Non Current Assets |
|
0.29
+27.56%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Total Liabilities Net Minority Interest |
|
53.48
-22.97%
|
69.43
+226.36%
|
21.27
-34.18%
|
32.32
|
| Current Liabilities |
|
45.44
-4.13%
|
47.40
+122.80%
|
21.27
-31.77%
|
31.18
|
| Payables And Accrued Expenses |
|
20.84
+23.20%
|
16.92
+26.79%
|
13.34
-43.52%
|
23.63
|
| Payables |
|
5.52
+26.18%
|
4.38
+402.64%
|
0.87
-78.52%
|
4.05
|
| Accounts Payable |
|
5.34
+230.59%
|
1.61
+109.20%
|
0.77
-78.79%
|
3.64
|
| Other Payable |
|
0.18
+150.00%
|
0.07
-25.25%
|
0.10
-76.14%
|
0.41
|
| Current Accrued Expenses |
|
15.32
+22.16%
|
12.54
+0.55%
|
12.47
-36.27%
|
19.57
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
12.76
+15.22%
|
11.08
+63.25%
|
6.79
+36.62%
|
4.97
|
| Total Tax Payable |
|
0.00
-100.00%
|
2.69
|
0.00
|
—
|
| Income Tax Payable |
|
0.00
-100.00%
|
2.69
|
0.00
|
—
|
| Current Debt And Capital Lease Obligation |
|
2.28
+347.65%
|
0.51
-55.30%
|
1.14
-54.63%
|
2.52
|
| Current Capital Lease Obligation |
|
2.28
+347.65%
|
0.51
-55.30%
|
1.14
-54.63%
|
2.52
|
| Current Deferred Liabilities |
|
9.55
-49.45%
|
18.89
+629600.00%
|
0.00
-95.65%
|
0.07
|
| Current Deferred Revenue |
|
9.55
-49.45%
|
18.89
+629600.00%
|
0.00
-95.65%
|
0.07
|
| Total Non Current Liabilities Net Minority Interest |
|
8.04
-63.51%
|
22.03
|
0.00
-100.00%
|
1.14
|
| Long Term Debt And Capital Lease Obligation |
|
8.04
-22.36%
|
10.36
|
0.00
-100.00%
|
1.14
|
| Long Term Capital Lease Obligation |
|
8.04
-22.36%
|
10.36
|
0.00
-100.00%
|
1.14
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
11.68
|
0.00
|
—
|
| Stockholders Equity |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Common Stock Equity |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
62.58
+2.53%
|
61.04
+5.76%
|
57.71
+16.96%
|
49.34
|
| Ordinary Shares Number |
|
62.58
+2.53%
|
61.04
+5.76%
|
57.71
+16.96%
|
49.34
|
| Additional Paid In Capital |
|
1,084.74
+6.78%
|
1,015.90
+6.66%
|
952.49
+26.54%
|
752.72
|
| Retained Earnings |
|
-470.67
-38.22%
|
-340.52
+44.69%
|
-615.71
-14.71%
|
-536.75
|
| Gains Losses Not Affecting Retained Earnings |
|
0.64
+881.71%
|
-0.08
+21.90%
|
-0.10
+70.75%
|
-0.36
|
| Other Equity Adjustments |
|
0.64
+881.71%
|
-0.08
+21.90%
|
-0.10
+70.75%
|
-0.36
|
| Total Equity Gross Minority Interest |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Total Capitalization |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Working Capital |
|
532.13
-2.23%
|
544.24
+62.80%
|
334.30
+57.77%
|
211.90
|
| Invested Capital |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Total Debt |
|
10.32
-5.00%
|
10.87
+852.32%
|
1.14
-68.79%
|
3.66
|
| Capital Lease Obligations |
|
10.32
-5.00%
|
10.87
+852.32%
|
1.14
-68.79%
|
3.66
|
| Net Tangible Assets |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Tangible Book Value |
|
614.71
-8.97%
|
675.29
+100.58%
|
336.68
+56.15%
|
215.61
|
| Duefrom Related Parties Current |
|
0.12
-99.93%
|
165.00
+1550.00%
|
10.00
+99900.00%
|
0.01
|
| Dueto Related Parties Current |
|
—
|
—
|
—
|
0.07
|
| Investmentin Financial Assets |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
57.67
-68.68%
|
184.15
+362.19%
|
-70.24
+35.05%
|
-108.14
|
| Cash Flow From Continuing Operating Activities |
|
57.67
-68.68%
|
184.15
+362.19%
|
-70.24
+35.05%
|
-108.14
|
| Net Income From Continuing Operations |
|
-130.15
-147.29%
|
275.19
+448.54%
|
-78.95
+38.02%
|
-127.39
|
| Depreciation Amortization Depletion |
|
1.28
+54.96%
|
0.83
-15.46%
|
0.98
-5.51%
|
1.03
|
| Depreciation |
|
1.28
+54.96%
|
0.83
-15.46%
|
0.98
-5.51%
|
1.03
|
| Depreciation And Amortization |
|
1.28
+54.96%
|
0.83
-15.46%
|
0.98
-5.51%
|
1.03
|
| Other Non Cash Items |
|
1.58
-23.63%
|
2.07
-18.19%
|
2.53
+8.31%
|
2.33
|
| Stock Based Compensation |
|
45.97
+22.42%
|
37.55
+28.20%
|
29.29
+21.04%
|
24.20
|
| Deferred Tax |
|
—
|
—
|
—
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
0.00
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
146.21
+219.25%
|
-122.61
-528.41%
|
-19.51
-151.24%
|
-7.77
|
| Change In Receivables |
|
164.88
+206.37%
|
-155.00
-1451.55%
|
-9.99
-335.50%
|
4.24
|
| Change In Prepaid Assets |
|
-2.36
+37.37%
|
-3.77
-314.95%
|
1.75
-53.30%
|
3.75
|
| Change In Payables And Accrued Expense |
|
5.61
-28.23%
|
7.82
+191.63%
|
-8.53
+25.82%
|
-11.50
|
| Change In Accrued Expense |
|
4.58
+6.69%
|
4.29
+176.63%
|
-5.60
+55.98%
|
-12.71
|
| Change In Payable |
|
1.03
-70.69%
|
3.53
+220.25%
|
-2.93
-341.48%
|
1.22
|
| Change In Account Payable |
|
3.72
+342.16%
|
0.84
+129.36%
|
-2.87
-240.24%
|
2.04
|
| Change In Other Working Capital |
|
-21.02
-168.76%
|
30.57
|
—
|
-1.60
|
| Change In Other Current Liabilities |
|
-0.90
+59.43%
|
-2.23
+18.85%
|
-2.74
-3.08%
|
-2.66
|
| Investing Cash Flow |
|
-49.33
+83.53%
|
-299.48
-662.86%
|
-39.26
-142.92%
|
91.47
|
| Cash Flow From Continuing Investing Activities |
|
-49.33
+83.53%
|
-299.48
-662.86%
|
-39.26
-142.92%
|
91.47
|
| Net PPE Purchase And Sale |
|
-1.59
-17.34%
|
-1.35
-122.50%
|
-0.61
+23.40%
|
-0.80
|
| Purchase Of PPE |
|
-1.59
-17.34%
|
-1.35
-122.50%
|
-0.61
+23.40%
|
-0.80
|
| Capital Expenditure |
|
-1.59
-17.34%
|
-1.35
-122.50%
|
-0.61
+23.40%
|
-0.80
|
| Net Investment Purchase And Sale |
|
-47.74
+83.99%
|
-298.13
-671.37%
|
-38.65
-141.89%
|
92.26
|
| Purchase Of Investment |
|
-546.59
+12.08%
|
-621.70
-225.42%
|
-191.04
+11.09%
|
-214.87
|
| Sale Of Investment |
|
498.84
+54.17%
|
323.57
+112.32%
|
152.40
-50.38%
|
307.14
|
| Financing Cash Flow |
|
22.86
-11.56%
|
25.85
-84.83%
|
170.48
+804.96%
|
18.84
|
| Cash Flow From Continuing Financing Activities |
|
22.86
-11.56%
|
25.85
-84.83%
|
170.48
+804.96%
|
18.84
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
132.10
+807.72%
|
14.55
|
| Proceeds From Stock Option Exercised |
|
23.34
-11.76%
|
26.45
-32.42%
|
39.15
+780.08%
|
4.45
|
| Net Other Financing Charges |
|
-0.48
+20.17%
|
-0.60
+21.98%
|
-0.77
-371.78%
|
-0.16
|
| Changes In Cash |
|
31.20
+134.87%
|
-89.48
-246.73%
|
60.98
+2711.57%
|
2.17
|
| Effect Of Exchange Rate Changes |
|
—
|
0.00
|
0.00
+100.00%
|
-0.09
|
| Beginning Cash Position |
|
97.47
-47.86%
|
186.95
+48.41%
|
125.97
+1.68%
|
123.89
|
| End Cash Position |
|
128.68
+32.01%
|
97.47
-47.86%
|
186.95
+48.41%
|
125.97
|
| Free Cash Flow |
|
56.08
-69.32%
|
182.80
+358.02%
|
-70.84
+34.96%
|
-108.93
|
| Interest Paid Supplemental Data |
|
3.69
+141.44%
|
1.53
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-7.22
+18.61%
|
-8.88
-94.24%
|
-4.57
-732.24%
|
-0.55
|
| Change In Income Tax Payable |
|
-2.69
-200.00%
|
2.69
|
0.00
|
0.00
|
| Change In Tax Payable |
|
-2.69
-200.00%
|
2.69
|
0.00
|
0.00
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
132.10
+807.72%
|
14.55
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
132.10
+807.72%
|
14.55
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-25 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 42026-02-18 View
- 42026-02-06 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-13 View
- 8-K2026-01-12 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|